AtriCure (ATRC)

• Market cap: $1.87B
• 1 day: 0.48%
• 5 days: 6.80%
• 1 month: 20.13%
• 3 months: 11.33%
• 6 months: -4.03%
• Year to date: 24.47%
• 1 year: 44.70%
• 5 years: -8.42%
• 10 years: 52.21%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Employees: 1,300

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

8% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 71

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

1% less capital invested

Capital invested by funds: $1.62B [Q1] → $1.6B (-$22.3M) [Q2]

4.21% less ownership

Funds ownership: 102.84% [Q1] → 98.64% (-4.21%) [Q2]

11% less funds holding

Funds holding: 219 [Q1] → 196 (-23) [Q2]

51% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 35

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $45 19% upside
• Avg. target: $45 19% upside
• High target: $45 19% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Needham Mike Matson

19% upside $45

Buy Maintained

30 Jul 2025